Antibody-directed therapies for hematological malignancies

Trends in Molecular Medicine

Volumn 8, Issue 2, 2002, Pages 69-76

  Linenberger, Michael L ^a   Maloney, David G ^a   Bernstein, Irwin D ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL TOXIN; GEMTUZUMAB OZOGAMICIN; IMMUNOTOXIN; IODINE 131; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD 20; RITUXIMAB; UNCLASSIFIED DRUG; YTTRIUM 90;

ANTIGEN EXPRESSION; DRUG CONJUGATION; DRUG DESIGN; DRUG MECHANISM; HEMATOLOGIC DISEASE; HEMATOPOIETIC CELL; HUMAN; LEUKEMIA; NONHODGKIN LYMPHOMA; NONHUMAN; REVIEW;

BACTERIA (MICROORGANISMS);

EID: 0036158010     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4914(02)02278-5     Document Type: Review

References (53)

1. Continuous cultures of fused cells secreting antibody of predefined specificity
2. The development of monoclonal antibodies for the therapy of cancer
3. Newer treatments for non-Hodgkin's lymphoma: Monoclonal antibodies
4. Immunotherapy for non-Hodgkin's lymphoma
5. Current uses of monoclonal antibodies in the treatment of acute leukemia
6. Antiidiotype antibody therapy of B-cell lymphoma
7. Lymphoma regression induced by monoclonal anti-idiotypic antibodies correlates with their ability to induce Ig signal transduction and is not prevented by tumor expression of high levels of bcl-2 protein
8. Overview of the clinical development of rituximab: First monoclonal antibody approved for the treatment of lymphoma
9. Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells
10. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis
11. Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: A retrospective analysis on 32 patients
12. A phase I/II trial of iodine- 131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas
13. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma
14. Phase I study of (131)I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome
15. Campath-1H monoclonal antibody therapy
16. Monoclonal antibody drug conjugates in the treatment of cancer
17. Immunotoxins in cancer therapy
18. Cytotoxic potency of CD22-ricin A depends on intracellular routing rather than on the number of internalized molecules
19. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse
20. Treatment of lymphoma with radiolabeled antibody: Elimination of tumor cells lacking target antigen
21. Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells
22. A new era for radiolabeled antibodies in cancer?
23. Radioimmunotherapy with iodine (131) tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: Updated results and long-term follow-up of the University of Michigan experience
24. Pharmacokinetics and dosimetry of an alpha-particle emitter labeled antibody: 213Bi-HuM195 (anti-CD33) in patients with leukemia
25. A combination of anti-CD3 and anti-CD7 ricin A-immunotoxins for the in vivo treatment of acute graft versus host disease
26. Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies
27. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia
28. Monoclonal antibody conjugates of doxorubicin prepared with branched linkers: A novel method for increasing the potency of doxorubicin immunoconjugates
29. Sterically stabilized anti-idiotype immunoliposomes improve the therapeutic efficacy of doxorubicin in a murine B-cell lymphoma model
30. Treatment of therapy-refractory B-lineage acute lymphoblastic leukemia with an apoptosis-inducing CD 19-directed tyrosine kinase inhibitor
31. Calicheamicin gamma 1I: An antitumor antibiotic that cleaves double-stranded DNA site specifically
32. Structure, distribution, and functional role of protection (CD59) in complement-susceptibility and in immunotherapy of human malignancies
33. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression
34. Emergence of idiotype variants during treatment of B-cell lymphoma with anti-idiotype antibodies
35. Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab zogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein expressing sublines
36. Multidrug resistance phenotype and clinical responses to gemtuzumab ozogamicin
37. Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs
38. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody for cancer therapy
39. Antibody engineering
40. Identification of a human anti-CD55 single-chain Fv by subtractive panning of a phage library using tumor and nontumor cell lines
41. Anti-CD16/CD30 bispecific antibody treatment for Hodgkin's disease: Role of infusion schedule and costimulation with cytokines
42. Locoregional treatment of low-grade B-cell lymphoma with CD3×CD19 bispecific antibodies and CD28 costimulation: I. Clinical phase I evaluation
43. Construction and characterization of a fusion protein of single-chain anti-CD20 antibody and human β-glucuronidase for antibody-directed enzyme prodrug therapy
44. Potent and specific antitumor effects of an anti-CD22-targeted cytotoxic ribonuclease: Potential for the treatment of non-Hodgkin lymphoma
45. Influence of cytotoxicity enhancers in combination with human serum on the activity of CD22-recombinant ricin A against B cell lines, chronic and acute lymphocytic leukemia cells
46. Infarction of solid Hodgkin's tumors in mice by antibody-directed targeting of tissue factor to tumor vasculature
47. Therapeutic application of anti-growth factor receptor antibodies
48. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy
49. Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma
50. Mabthera (rituximab) plus CHOP is superior to CHOP alone in elderly patients with diffuse large B-cell lymphoma (DLCL): Interim results of a randomized GELA trial
51. Increased inhibition of proliferation of human B cell lymphomas following ligation of CD40, and either CD19, CD20, CD95 or surface immunoglobulin
52. Systemic therapy with 3BIT, a triple combination cocktail of anti-CD19, -CD22, and -CD38-saporin immunotoxins, is curative of human B-cell lymphoma in severe combined immunodeficient mice
53. Immunotoxins against CD19 and CD22 are effective in killing precursor-B acute lymphoblastic leukemia cells in vitro